A Novel HPLC Method for Determination of Phenytoin in Human Plasma

Jesse Flores
*Touro College of Pharmacy*

Sheril Alexander
*Touro College of Pharmacy*

Mariana Babayeva
*Touro College of Pharmacy*, mariana.babayeva@touro.edu

Follow this and additional works at: [https://touroscholar.touro.edu/tcopny_pubs](https://touroscholar.touro.edu/tcopny_pubs)

Part of the Medicinal and Pharmaceutical Chemistry Commons

**Recommended Citation**
Flores, J., Alexander, S., & Babayeva, M. (2018). A novel HPLC method for determination of phenytoin in human plasma. *Journal of Pharmaceutical Research International, 22*(6), 1-7. doi:10.9734/JPRI/2018/41885
A Novel HPLC Method for Determination of Phenytoin in Human Plasma

Jesse Flores¹, Sheril Alexander¹ and Mariana Babayeva¹

¹Department of Biomedical and Pharmaceutical Sciences, Touro College of Pharmacy, New York, USA.

Authors’ contributions

This work was carried out in collaboration between all authors. Author JF conducted validation of the HPLC method and wrote the first draft of the manuscript. Author SA developed the analytical method. Author MB managed the study. All authors read and approved the final manuscript.

ABSTRACT

Aim: The aim of this research was to develop and validate a simple, efficient and reproducible high-performance liquid chromatography method to measure phenytoin concentrations in human plasma.

Study Design: Linearity, selectivity, sensitivity, accuracy and precision of the analytical methods were validated according to ICH guidelines.

Methodology: The method employed a Phenomenex C₁₈ column kept at 25°C. The mobile phase consisted of a 0.05 M potassium dihydrogen phosphate buffer solution (pH 2.8) and methanol in a ratio of 60:40, respectively. The flow rate of the mobile phase was 0.7 mL/min. Phenytoin was detected at a wavelength of 250 nm.

Results: Phenytoin was eluted at 7.4 minutes with no interference with the other components of the human plasma. The method was linear in the range of 1-25 μg/mL ($R^2 = 0.9998$). The LOD and LOQ were calculated as 0.07 μg/mL and 0.20 μg/mL, respectively. Recovery, tested in the range of 5-20 μg/mL, was found to be 99.21 - 102.09%. Intraday and interday precision RSDs were 0.65 and 5.77%.

*Corresponding author: E-mail: mariana.babayeva@touro.edu;
Conclusion: The proposed method is fast, reliable and reproducible, and can be recommended to measure free phenytoin levels in the blood.

Keywords: Phenytoin; HPLC; validation; human plasma.

1. INTRODUCTION
Phenytoin (PHT) is an anticonvulsant medication marketed in the U.S. as Dilantin™. This drug has been indicated for the management of generalized tonic-clonic seizures, complex partial seizures, and for the prevention of seizures after head trauma and neurosurgery [1,2]. There is interest in examining the activity of the drug due to its narrow therapeutic index, nonlinear pharmacokinetics and the ability of various compounds to modify the concentrations of phenytoin in the blood [2-5]. Drugs in the body exist in two forms bound and unbound. Only unbound (free) drug reaches the active site, interacts with receptors and produces a therapeutic effect. Free drug is a predictor of clinical efficacy or toxicity [6-8]. PHT is approximately 90% bound to plasma proteins [9-11]. Changes in unbound concentrations of PHT can lead to exaggerated pharmacologic response and toxicity. The development of side effects also correlates better with free phenytoin concentrations than with total concentrations [12-14]. PHT, as a drug with nonlinear pharmacokinetics and narrow therapeutic index, may produce major changes in the pharmacological effect with the only small variations in its unbound plasma concentrations. Monitoring of free PHT plasma levels is required to avoid unexpected alterations in pharmacologic response, to achieve the efficacy of phenytoin and to avoid phenytoin intoxication. Unbound phenytoin plasma concentrations should be measured in patients rather than calculated [15]. Our study aimed to develop a simple, efficient and reproducible high-performance liquid chromatography (HPLC) method to assess unbound PHT levels in human plasma. Previous studies have measured PHT levels using HPLC methods outside plasma [16,17], involved solid-phase extraction protocols [18] as well as detected PHT concentrations in biological fluids [19-25]. This novel HPLC method was used to assess free plasma concentrations of phenytoin in drug-drug interaction studies [26].

2. MATERIALS AND METHODS

2.1 Chemicals and Reagents
Phenytoin sodium (5,5-Diphenylhydantoin sodium salt), dimethyl sulfoxide (DMSO), HPLC-grade methanol, HPLC-grade water and 0.22 μm Stericup™ Sterile Vacuum Filter Units were obtained from Fisher Scientific (New Hampshire, USA). Potassium dihydrogen phosphate and Centrifree® Ultrafiltration Devices were purchased from EMD Millipore (Massachusetts, USA). Human plasma was obtained from Valley Biomedical (Virginia, USA).

2.2 Instrument and Chromatographic Conditions
An Agilent 1100 series HPLC system with autosampler and UV detector was used for the study. A Phenomenex Kinetex C18 LC column (250 x 4.6 mm) was operated at 25°C. An isocratic method was utilized to elute the analyte with a mobile phase flow rate of 0.7 mL/min. The injection volume was 20 µL for all samples. Phenytoin was detected at a wavelength of 250 nm.

2.3 Mobile Phase Preparation
The mobile phase consisted of a 0.05 M potassium dihydrogen phosphate (KH$_2$PO$_4$) buffer solution (pH adjusted to 2.8 with phosphoric acid) and methanol (MeOH) in a 60:40, MeOH:KH$_2$PO$_4$ ratio. The mobile phase was filtered using a 0.22 µm Stericup™ Sterile Vacuum Filter Unit and degassed by a vacuum stirring setup.

2.4 Stock Solution and Samples Preparation
Phenytoin was dissolved in HPLC-grade DMSO to produce a stock solution of 1 mg/mL concentration. The master stock was diluted with filtered human plasma to produce another stock solution of 100 µg/mL, which was further diluted to achieve required concentrations of phenytoin.
Human plasma was passed through Millipore ultracentrifugation units, which were run at 2,000X g for 20 minutes. The resulting filtrate was collected and used as a diluent for the PHT stock solution.

3. METHOD VALIDATION

The analytical method was validated based on ICH Harmonised Tripartite Guideline [27].

3.1 Specificity

The specificity of the method was determined by comparing blank (plasma without PHT) chromatogram to the chromatogram of a sample containing a known concentration of PHT. Analysis of the sample containing PHT showed a sharp peak at an elution time of 7.4 min, which was absent on the blank chromatogram (Figure 1). Other components of filtered plasma were detected and separated by the method, allowing proper visualization of the PHT peak. The experiments were performed in triplicate.

3.2 Linearity

To determine linearity, eight phenytoin concentrations ranging from 1 to 25 μg/mL were prepared from the stock solution. Filtered human plasma was used to dilute the PHT stock solution into 1, 2, 4, 6, 8, 10, 15 and 25 μg/mL concentrations. The samples were assessed to HPLC. The mean area for each concentration was plotted against the concentration (Fig. 2).

![Blank Chromatogram](image1.png)

**Fig. 1. Blank Chromatogram (top) and Phenytoin Chromatogram (bottom): PHT concentration is 25 μg/mL, retention time is 7.399 minutes**

![Linearity Plot](image2.png)

**Fig. 2. The linearity of the HPLC method**
An excellent correlation was detected between the peak areas and concentrations tested ($R^2 = 0.9998$). All experiments were performed in triplicate.

### 3.3 Limit of Detection and Limit of Quantitation

The limit of detection (LOD) and limit of quantitation (LOQ) were calculated based on ICH guidelines [11]. The following formulas were used:

$$LOD = 3.3\sigma/S$$
$$LOQ = 10\sigma/S$$

Where:

- $\sigma$ refers to the standard deviation of the y-intercept of the calibration curve
- $S$ refers to the slope of the calibration curve.

The calculated LOD and LOQ were at 0.07 μg/mL and 0.20 μg/mL, respectively (Table 1).

### 3.4 Accuracy

Accuracy study was performed with PHT concentrations of 5 μg/mL, 10 μg/mL and 20 μg/mL. Triplicates were made to assess the accuracy. The results of the study are summarized in Table 2. The mean % recoveries of the three concentrations were found in the range of 99.21 - 102.09%.

| Sample | PHT concentration (μg/mL) | Measured PHT Concentration(μg/mL) | % Recovery | Mean % Recovery |
|--------|---------------------------|-----------------------------------|------------|----------------|
| 1      | 5                         | 5.01                              | 100.28     | 100.55         |
|        |                            | 5.03                              | 100.67     |                |
|        |                            | 5.03                              | 100.68     |                |
| 2      | 10                        | 9.93                              | 99.27      |                |
|        |                            | 9.91                              | 99.15      | 99.21          |
|        |                            | 9.92                              | 99.22      |                |
| 3      | 20                        | 20.26                             | 101.28     | 102.09         |
|        |                            | 20.63                             | 103.17     |                |
|        |                            | 20.36                             | 101.81     |                |

### 3.5 Precision / Repeatability

Precision was determined by utilizing inter- and intraday testing. Phenytoin concentration of 25 μg/ml was used in both studies. In the intraday study, six injections of different samples of 25 μg/mL concentration were evaluated. In the interday study, an injection of six different samples of the same concentration (25 μg/mL) was done once a day for six consecutive days. The results of the study are summarized in Table 3. The results have been demonstrated low relative standard deviations (RSD) that indicate a precise method [28].

| Sample | Intraday Concentration(μg/mL) | Interday Concentration(μg/mL) | Day |
|--------|-------------------------------|-------------------------------|-----|
| 1      | 25.15                         | 25.13                         | 1   |
| 2      | 24.90                         | 25.14                         | 2   |
| 3      | 24.80                         | 25.03                         | 3   |
| 4      | 24.85                         | 25.16                         | 4   |
| 5      | 25.25                         | 25.01                         | 5   |
| 6      | 25.03                         | 24.97                         | 6   |
| Mean   | 24.99                         | 25.07                         |     |
| SD*    | 0.16                          | 0.07                          |     |
| %RSD** | 0.65                          | 0.29                          |     |

*SD is Standard Deviation
**RSD is Relative Standard Deviation
Table 4. Stability of phenytoin

| Initial PHT concentration (μg/mL) | Stability conditions | Mobile phase |
|----------------------------------|----------------------|--------------|
|                                  | Human plasma         |              |
|                                  | RT, 4h 4°C, 24 h     | -30°C, 7 days|
|                                  | Freeze-Thaw 4°C 24 h |              |
| 5                                | 5.06                 | 5.01         |
| 25                               | 25.17                | 25.13        |

3.6 Stability

The stability of phenytoin in human plasma was evaluated and the results are reported in Table 4.

All the samples demonstrated stability for up to 4 h at room temperature (RT), for 24 h at 4°C, for 7 days at −30°C and after three freeze-thaw cycles.

4. CONCLUSION

The goal of the study was to develop and validate a simple and effective HPLC method to measure unbound phenytoin concentrations in human plasma. The analytical technique was fully validated. The novel HPLC method demonstrated phenytoin sharp peak, good resolution and no interferences from plasma constituents. The analytical procedure is a simple, fast, selective, precise and accurate method for quantitation of phenytoin in human plasma and may be utilized in studies where free phenytoin levels need to be measured. Detecting of free PHT plasma levels should be conducted to escape variations in pharmacologic response, to achieve the efficacy of phenytoin and to avoid phenytoin intoxication novel HPLC method has the necessary sensitivity to be used clinically for TDM (therapeutic drug monitoring) as well as for pharmacokinetics and drug: drug interaction studies. The this newly developed analytical technique has been applied for the drug: drug interaction studies between phenytoin and tizoxanide [26].

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Neuvonen PJ. Bioavailability of phenytoin: Clinical pharmacokinetic and therapeutic implications. Clinical Pharmacokinetics. 1979;4(2):91-103.
2. Product Monograph. Available: http://www.pfizer.ca/sites/g/files/g10017036/f/201410/DILANTIN.pdf (Assessed 15 April 2018)
3. Lecomte M, Zini R, D’Athis P, Tillement JP. Phenytoin binding to human albumin. European Journal of Drug Metabolism and Pharmacokinetics. 1979;4(1):23–28
4. Perucca E. Plasma protein binding of phenytoin in health and disease. Therapeutic Drug Monitoring. 1980; 2(4):331–344.
5. Richens A. Clinical pharmacokinetics of phenytoin. Clinical Pharmacokinetics. 1979;4(3):153-69.
6. Schmidt S, Gonzalez D, Derendorf H. Significance of protein binding in pharmacokinetics and pharmacodynamics. Journal of Pharmaceutical Sciences. 2010; 99(3):1107-1122.
7. Bohnert T, Gan LS. Plasma protein binding: from discovery to development. Journal of Pharmaceutical Sciences. 2013; 102(9): 2953-2994.
8. Mullokandov E, Ahn J, Szalkiewicz A, Babayeva M. Protein binding drug-drug interaction between warfarin and tizoxanide in human plasma. Austin Journal of Pharmacology and Therapeutics. 2014;2(7):3.
9. Au Yeung SC, Ensom MH. Phenytoin and enteral feedings: Does evidence
support an interaction? Annals of Pharmacotherapy. 2000;34:896-905.

10. Markowsky SJ, Skaar DJ, Christie JM, Eyer SD, Ehresman DJ. Phenytoin protein binding and dosage requirements during acute and convalescent phases following brain injury. Annals of Pharmacotherapy. 1990;30(5):443-448.

11. Lecomte M, Zini R, D’Athis P, Tillement JP. Phenytoin binding to human albumin. European Journal of Drug Metabolism and Pharmacokinetics. 1979;4(1):23–28.

12. Banh HL, Burton ME, Sperling MR. Interpatient and intrapatient variability in phenytoin protein binding. Therapeutic Drug Monitoring. 2002;24:379-85.

13. Peterson GM, Khoo BH, von Witt RJ. Clinical response in epilepsy in relation to total and free serum levels of phenytoin. Therapeutic Drug Monitoring. 1991;13:415-9.

14. Cohen H. Casebook in clinical pharmacokinetics and drug dosing. New York: McGraw-Hill; 2015.

15. Hong JM, Choi YC, Kim WJ. Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients. Yonsei Medical Journal. 2009;50(4):517-520.

16. Shan R, Shan R. Development and validation of RP-HPLC method for phenytoin sodium and phenobarbitone in bulk and pharmaceutical dosage form. International Journal of Pharmacy and Pharmaceutical Sciences. 2017;9(10):224-229.

17. Ravichandran S, Valliappan K, Ramanathan M. Validated RP-HPLC method for concurrent determination of phenytoin sodium and clopidogrel bisulphate in tablet dosage form. Journal of Pharmaceutical Sciences and Research. 2015;7(11):934-937.

18. Roy SM, Yetal SM, Vaidya VV, Joshi SS. Determination and quantification of phenytoin in human plasma by liquid chromatography with electrospRAY ionization tandem mass spectrometry. E-Journal of Chemistry. 2008;5(1):169-176.

19. Lin P, Hsieh Y, Liao F, Chen S. Determination of free and total levels of phenytoin in human plasma from patients with epilepsy by MEKC: An adequate alternative to HPLC. Electrophoresis. 2010;31(9):1572-82.

20. Serralheiro A, Alves G, Fortuna A, Rocha M, Falcão A. First HPLC-UV method for rapid and simultaneous quantification of phenobarbital, primidone, phenytoin, carbamazepine, carbamazepine-10,11-epoxide, 10,11-trans-dihydroxy-10,11-dihydrocarbamazepine, lamotrigine, oxcarbazepine and licarbazepine in human plasma. J Chromatogr B Analyl Technol Biomed Life Sci. 2013;925:1-9.

21. Bhatti MM, Hanson GD and Schultz L. Simultaneous determination of phenytoin, carbamazepine, and 10,11-carbamazepine epoxide in human plasma by high-performance liquid chromatography with ultraviolet detection. Journal of Pharmaceutical and Biomedical Analysis. 1998;16(7):1233–1240.

22. Owik MJ, Liang M, Deyo K, Andrews C, Fischer J. Simultaneous rapid high-performance liquid chromatographic determination of phenytoin and its prodrug, fosphenytoin in human plasma and ultrafiltrate. J Chromatogr B Biomed Sci Appl. 1997;693(2):407-14.

23. Matar, KM, Nicholls PJ, Tekle A, Bawazir SA and Al-Hassan MI. Liquid chromatographic determination of six antiepileptic drugs and two metabolites in microsamples of human plasma. Therapeutic Drug Monitoring. 1999;21(5):559–566.

24. Asadi M, Dadfarnia S, Haji Shabani AM, Abbasi B. Simultaneous extraction and quantification of lamotrigine, phenobarbital, and phenytoin in human plasma and urine samples using solidified floating organic drop microextraction and high-performance liquid chromatography. J Sep Sci. 2015;38(14):2510-6.

25. Ferreira A, Rodrigues M, Oliveira P, Francisco J, Fortuna A, Rosado L, Rosado P, Falcão A, Alves G. Liquid chromatographic assay based on microextraction by packed sorbent for therapeutic drug monitoring of carbamazepine, lamotrigine, oxcarbazepine, phenobarbital, phenytoin and the active metabolites carbamazepine-10,11-epoxide and licarbazepine. Journal of Chromatography B. 2014;971:20–9.

26. Alexander S, Flores J, Ofuluozor H, Babayeva M. Significant Inhibition of Protein Binding of Phenytoin. JAMMR. 2018;25(11):1-7.
27. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Available: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1_Guideline.pdf (Assessed 15 April 2018)

28. Sharma R, Mishra PG, Chaturvedi SC. Development and validation of RP-HPLC method for the simultaneous determination of rabeprazole sodium and itopride hydrochloride in solid dosage form. E-Journal of Chemistry. 2010;7(3):947–952.

© 2018 Flores et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sciencedomain.org/review-history/25422